Take Home Messages
Multikinase inhibitors with antitumoral and antiangiogenic
effects have demonstrated meaningful efficacy in RAI-
refractory DTC:
Sorafenib and Lenvatinib
Lenvatinib has demonstrated higher efficacy in terms of
response rate and PFS advantage, suggesting an impact in
overall survival even after cross-over design
Lenvatinib has showed rapid, deeply and prolonged
responses that reach a mPFS similar to the mOS expected
prior TKIs therapy arrival in advanced thyroid cancer
